This Trio of Blood Tests Predict 30-Year Cardiovascular Disease Risks for Women
Analysis by Dr. Joseph Mercola
Reviewed by Keith W. Vrbicky, Sr., MD
October 24, 2024
STORY AT-A-GLANCE
- Cardiovascular disease (CVD) is the leading cause of death among women in the U.S., affecting nearly 44% of the female population — over 60 million women
- A 30-year study published in August 2024 used a trio of blood tests to examine three key biomarkers — high sensitivity CRP (hs-CRP), LDL cholesterol and Lp(a) — and determine how they influence long-term cardiovascular disease
- High sensitivity-CRP measures inflammation, LDL cholesterol measures atherosclerosis risk and Lp(a) indicates the risk of plaque formation and blood clotting. Lower levels of these biomarkers are generally better for cardiovascular health
- The study found that higher baseline levels of all three biomarkers were strongly linked to increased 30-year cardiovascular risk, with hs-CRP showing the strongest association
- The researchers suggest implementing early interventions as early as 30 to 40 years old to effectively reduce the risk of CVD. Strategies to protect your cardiovascular health are included below
Call Midwest Health Partners about Itamar Medical’s EndoPAT – the only FDA-cleared test for the non-invasive assessment of Endothelial Dysfunction (arterial health); clinically proven by leading cardiologists through prestigious peer-reviewed studies as a valuable tool in cardiovascular risk stratification beyond commonly used tests.